![Patrick Yeramian](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrick Yeramian
Corporate Officer/Principal en
Dlx Therapeutics L L C
.
Perfil
Patrick D.
Yeramian is currently the General Manager at Dlx Therapeutics L L C.
Previously, he worked as a Medical Director at Pfizer Inc., Marker Therapeutics, Inc., Vaccine & Gene Therapy Institute of Florida Corp., Kantum Pharma, Inc., and Tapimmune, Inc. He also served as the Director-Clinical Research at G.D.
Searle LLC and as the Chief Medical Officer at Viragen, Inc. and BioVie, Inc. Additionally, he is currently the Chief Medical Officer & Global Head-Clinical R&D at Amylyx Pharmaceuticals, Inc. Dr. Yeramian holds a graduate degree from Université de Paris XI Paris Sud, a doctorate from Universite Paris Est.
Creteil Val De Marne, and an MBA from Rutgers Business School.
Cargos activos de Patrick Yeramian
| Empresas | Cargo | Inicio |
|---|---|---|
Dlx Therapeutics L L C | Corporate Officer/Principal | 01/01/2018 |
Antiguos cargos conocidos de Patrick Yeramian.
| Empresas | Cargo | Fin |
|---|---|---|
| AMYLYX PHARMACEUTICALS, INC. | Director Técnico/Científico/I+D | 28/11/2023 |
| BIOVIE INC. | Director Técnico/Científico/I+D | 01/11/2021 |
Kantum Pharma, Inc.
 Kantum Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Develops novel and receptor antagonist-based therapeutics for AKI diagnostic tests | Director Técnico/Científico/I+D | 01/03/2019 |
| MARKER THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 01/01/2017 |
Tapimmune, Inc. | Director Técnico/Científico/I+D | 01/01/2017 |
Formación de Patrick Yeramian.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
15
Relaciones de 1er grado
13
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 13 |
|---|---|
Pfizer Inc.
 Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Viragen, Inc.
 Viragen, Inc. BiotechnologyHealth Technology Develops and researches immunological products | Health Technology |
Marker Therapeutics, Inc.
 Marker Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes cell based immune therapeutics and vaccines for cancer treatment | Health Technology |
BioVie, Inc.
 BioVie, Inc. BiotechnologyHealth Technology Develops drug therapies for chronic debilitating conditions | Health Technology |
Université de Paris XI Paris Sud
 Université de Paris XI Paris Sud Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Universite Paris Est Creteil Val De Marne
 Universite Paris Est Creteil Val De Marne Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
G.D. Searle LLC | |
Rutgers Business School
 Rutgers Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vaccine & Gene Therapy Institute of Florida Corp.
 Vaccine & Gene Therapy Institute of Florida Corp. Miscellaneous Commercial ServicesCommercial Services Provides research services | Commercial Services |
Amylyx Pharmaceuticals, Inc.
 Amylyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products to cure neurodegenerative diseases | Health Technology |
Kantum Pharma, Inc.
Kantum Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Develops novel and receptor antagonist-based therapeutics for AKI diagnostic tests | Commercial Services |
Dlx Therapeutics L L C | |
Tapimmune, Inc. |
- Bolsa de valores
- Insiders
- Patrick Yeramian
